Orum Therapeutics to Participate in SVB Leerink Biopharma Private Company Connect 

On October 20, 2021 Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, reported that members of its management team will be participating in the SVB Leerink Biopharma Private Company Connect Event (Press release, Orum Therapeutics, OCT 20, 2021, View Source [SID1234591592]). The event will take place virtually October 27-29, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!